Table 2 Association of Osteopontin splice variants with various cancers and their stage in TSVdb. Only the significant p-values (< 0.05 according to one-tailed t-test assuming equal variance) are listed. Left Panel) Comparison of cancer versus healthy (normal) tissue (h), primary tumor versus metastasis (m), or original cancer versus recurrence (r). All significant changes are high in cancer/in metastasis/in recurrence. Right panel) Significant changes in Osteopontin splice variant expression with tumor stage. Where multiple stages are significant, the highest p-value is listed and the smallest n. With the exception of entries in italics, all significant changes reflect increases. I/II = stage I versus stage II, I/III = stage I versus stage III, I/IV = stage I versus stage IV, II/IV = stage II versus stage IV, 6,7,8,9,10 = Gleason stages

adrenocortical carcinoma

79

pheochromocytoma/paraganglioma

187

kidney chromophobe

91

41

0.039 (I/IV)

renal clear cell carcinoma

605

11.6E-5 (h)

2.5E-5 (h)

500

15.3E-3 (I/II,I/III)

renal papillary cell carcinoma

323

1.02E-5 (h)

2.67E-3 (h)

2.21E-6 (h)

2.77E-6 (h)

210

0.011 (I/II)

4.8E-3 (I/II)

bladder urothelial carcinoma

427

prostate adenocarcinoma

550

550

0.03 (6/7–6/10)

0.02 (6/7–6/10)

0.04 (6/7–6/10)

testicular germ cell tumor

156

82

0.028 (I/II,I/III)

0.011 (I/III)

0.004 (I/III)

ovarian serous cystadenocarcinoma

307

4.67E-2 (r)

cervical cancers

309

endometrial carcinoma

201

0.022 (h)

0.018 (h)

3.78E-3 (h)

uterine carcinosarcoma

57

42

0.02 (I/III)

breast adenocarcinoma

1212

6.11E-9 (h)

2.27E-10 (h)

5.45E-5 (h)

222

0.034 (I/IV)

esophageal carcinoma

196

163

0.028 (I/II,I/III,I/IV)

0.028 (I/II,I/III,I/IV)

0.035 (I/II,I/III,I/IV)

0.012 (I/II,I/III)

0.048 (I/II,I/III,I/IV)

stomach adenocarcinoma

450

0.019 (h)

0.039 (h)

0.034 (h)

0.029 (h)

0.043 (h)

65

0.037 (I/IV)

0.036 (I/IV)

0.022 (I/IV)

colon adenocarcinoma

328

4.53E-4 (h)

3.58E-4 (h)

4.17E-4 (h)

137

0.012 (I/III)

0.022 (I/III)

0.011 (I/III)

0.007 (I/III)

rectum adenocarcinoma

105

31

0.007 (I/IV)

0.012 (I/IV)

0.010 (I/IV)

0.023 (I/IV)

cholangiocarcinoma

45

9.90E-3 (h)

3.27E-3 (h)

22.4E-3 (h)

8.06E-3 (h)

hepatocellular carcinoma

423

8.22E-4 (h)

6.36E-3 (h)

7.05E-3 (h)

6.69E-3 (h)

196

1.72E-4 (I/IV)

pancreatic adenocarcinoma

183

5.15E-4 (h)

1.28E-3 (h)

3.84E-3 (h)

5.72E-2 (h)

72

0.020 (I/II)

0.016 (I/II)

0.013 (I/II)

lung adenocarcinoma

576

1.73E-6 (h)

0.013 (h)

2.17E-6 (h)

1.02E-5 (h)

lung squamous cell carcinoma

552

1.05E-6 (h)

0.021 (h)

3.70E-5 (h)

8.42E-3 (h)

361

0.031 (I/II)

0.015 (I/III)

0.020 (I/II)

mesothelioma

87

thyroid carcinoma

568

0.010 (h)

0.013 (h)

0.022 (h)

382

0.034 (I/II,I/III)

0.035 (I/II)

0.021 (I/II,I/III)

0.008 (I/III)

0.026 (I/III)

thymoma

122

43

0.021 (I/IV)

0.025 (I/IV)

0.028 (I/IV)

0.016 (I/IV)

0.005 (I/IV)

diffuse large B-cell lymphoma

48

acute myeloid leukemia

173

head and neck cancer

566

0.013 (h)

0.040 (h)

9.9E-3 (h)

0.039 (h)

119

0.028 (I/II,I/IV)

0.001 (I/II)

0.025 (I/II,I/IV)

0.013 (I/II)

glioblastoma

171

37.5E-3 (h)

35.9E-3 (h)

23.4E-3 (h)

brain lower grade glioma

530

cutaneous melanoma

473

0.012 (m)

0.028 (m)

2.67E-3 (m)

0.01 (m)

102

0.026 (I/IV)

5.77E-3 (I/IV)

17.9E-3 (I/II)

uveal melanoma

80

sarcoma

265